SEATTLE, Sept. 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that it has received a letter from The NASDAQ Stock Market LLC (the "NASDAQ"), indicating that CTI has regained compliance with the minimum bid price rule (NASDAQ Listing Rule 5550(a)(2)) .
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert Media Contact: Dan Eramian T: 206.272.4343C: 206.854.1200E: email@example.com www.CellTherapeutics.com/press_room Investors Contact: Ed BellT: 206.282.7100F: 206.272.4434E: firstname.lastname@example.org www.CellTherapeutics.com/investors SOURCE Cell Therapeutics, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts